The introduction of Cefdinir in the clinical practice expands the technological possibilities of the treatment of acute respiratory tract bacterial infections and urinary tract infections in children. What’s so special about this new technology – the use of Cefdinir?
The active substance is Cefdinir – semi-synthetic broad-spectrum cephalosporin antibiotic of the third generation for oral intake. Like other cephalosporin antibiotics, Cefdinir has an antibacterial effect on the sensitive microorganisms through the suppression of synthesis of peptidoglycan cell wall, caused by the violation of the final stage of transamination, required for the formation of lateral connections. However, it turns out that Cefdinir is also resistant to many beta-lactamases, produced by the gram-positive and gram-negative bacteria.
Because of that, many microorganisms, resistant to penicillin and some cephalosporins, prove to be sensitive to Cefdinir. The scope of action of Cefdinir is very wide. It includes:
- Aerobic gram-positive microorganisms: Staphylococcus aureus (including strains that produce beta-lactamases); Streptococcus pneumonia (only the strains sensitive to penicillin); Streptococcus pyogenes;
- Aerobic gram-negative microorganisms: Haemophilus influenzaе (including strains, that produce beta-lactamases); Haemophilus parainfluenzaе (including strains that produce beta-lactamases); Moraxella catarrhalis (including strains that produce beta-lactamases);
- Aerobic gram-positive microorganisms: Staphylococcus epidermidis; Streptococcus agalactiae; Streptococcus viridans;
- Aerobic gram-negative microorganisms: Citrobacter diversus; Escherichia coli; Klebsiela pneumoniae; Proteus mirabilis. However, Cefdinir is ineffective against the following strains: Pseudomonas, Enterobacter, Enterococcus and methicillin-resistant strains of staphylococcus. We should note that Cefdinir is considered the most effective oral cephalosporin of the third generation, used for the treatment of Streptococcus pneumoniae.
It is important for the pediatric practice that Cefdinir is allowed for the use in children over 6 months of age. There are special dosage forms of Cefdinir intended for the children. They are intended for the children from 6 months to 1 year:
- Cefdinir powder for the preparation of 60.0 ml of suspension; 125/5 ml in the bottle;
- Cefdinir powder for the preparation of suspension; 250 mg /5 ml in the bottle. Cefdinir is also available in capsules (each one contains 300 mg of the active substance). There are 10 capsules in the package.
Daily dosage of Cefdinir for children is 14 mg/kg of body weight. Maximum dosage is 600 mg. The drug has the following advantages:
- Possibility of dividing the daily dosage into 1–2 intake a day;
- Possibility of taking irrespective of the mealtime. These characteristics of Cefdinir are completely capable of increasing the commitment of patients and their parents to the treatment.
So, there are some obvious advantages of Cefdinir compared to the other cephalosporins of the third generation:
- Broad spectrum of action;
- Resistance to some beta-lactamases;
- More pronounced (compared to the other cephalosporins of the third generation) resistance to pneumococcus, as the most frequent agent of acute respiratory bacterial infections;
- Availability of pharmaceutical forms for children;
- Possibility of use in children over 6 months of age;
- Possibility of 1–2-time dosing;
- High tolerance.
These characteristics and the list of indications for use allows us to recommend buy cefdinir 300mg for the widespread introduction in the pediatric practice, particularly for the aetiotropic treatments of acute respiratory bacterial infections and the consistent antibiotic therapy after the parenteral introduction of cephalosporins of the third generation. Cefdinir is also considered as one of the drugs for the treatment of urinary tract infections.
So, the technological possibilities of aetiotropic treatment of acute respiratory bacterial infections and urinary tract infections during the outpatient treatment must be completed with the use of the new oral cephalosporin of the third generation of Cefdinir, which can be used in the first and the second situation, depending on the particular clinical situation.